Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 1999 January-February;51(1-2) > Minerva Ginecologica 1999 January-February;51(1-2):15-8

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA GINECOLOGICA

A Journal on Obstetrics and Gynecology


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index


eTOC

 

ORIGINAL ARTICLES  


Minerva Ginecologica 1999 January-February;51(1-2):15-8

Copyright © 1998 EDIZIONI MINERVA MEDICA

language: Italian

Ultrasonographic monitoring as a method of preventing the risks of ovarian hyperstimulation during pharmacological treatment

Grio R., Patriarca A., Ramondini L., Ferrara L., Curti A., Piacentino R.


PDF  


Background and aims. Ultrasonographic monitoring represents the most immediate method for an early confirmation of the onset of the worst complication of the pharmacological induction of ovulation: ovarian hyperstimulation. The aim of this study was to evaluate the incidence of this complication in a sample group of anovulatory patients receiving pharmacological treatment and undergoing repeated ultrasonographic monitoring.
Methods. The authors analysed the controls performed during 1996-1997 in which a total of 413 cycles were stimulated. The patients included in the study group (mean age 28.5 years) were treated using clomiphene, oestradiol, FSH, LH and GnRH, and in 5 cases stimulation was preceded by suppression of the menstrual cycle using tryptorelin. Each patient was monitored with 3 scans, except for those treated with tryptorelin or GnRH who were more closely monitored.
Results. In 413 patients included in this study the authors noted the onset of slight hyperstimulation in 6 cases (1.45%) which then resolved spontaneously without the need for hospitalisation.
Conclusions. The authors affirm that ultrasonographic monitoring represents a valid means of controlling and preventing the risks of ovarian hyperstimulation.

top of page

Publication History

Cite this article as

Corresponding author e-mail